---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-063959"
form_type: "8-K"
ticker: "TCRX"
cik: "0001783328"
company_name: "TScan Therapeutics, Inc."
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T13:17:25.775849+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# TScan Q1 net loss $34.1M; cash runway into Q1 2027; registrational trial H2 2025

## Summary
- Revenue $2.2M (up from $0.6M YoY); R&D expense $29.8M; net loss $34.1M vs $30.1M YoY.
- Cash, equivalents, and marketable securities $251.7M (plus $5.0M restricted) funding operations into Q1 2027.
- On track to initiate registrational trial for TSC-101 and file IND for TSC-102-A0301 in H2 2025.
- First patient dosing with multiplex TCR-T therapy expected H1 2025; safety/efficacy data by year-end.
- Appointed Stephen Camiolo as SVP Market Access; presenting at ASGCT and Bank of America conference.

## SEC filing metadata
- accession: 0000950170-25-063959
- form_type: 8-K
- ticker: TCRX
- cik: 0001783328
- company_name: TScan Therapeutics, Inc.
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783328/000095017025063959/0000950170-25-063959-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783328/000095017025063959/tcrx-20250506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-063959
- JSON: https://secwatch.observer/filing/0000950170-25-063959.json
- Plain text: https://secwatch.observer/filing/0000950170-25-063959.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.